In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection. (22nd February 2019)

• Record Type: Journal Article
• Authors: Rao, Gautham K; Prell, Rodney A; Laing, Steven T; Burleson, Stefanie C M; Nguyen, Allen; McBride, Jacqueline M; Zhang, Crystal; Sheinson, Daniel; Halpern, Wendy G
• Is Part Of: Toxicological sciences. Volume 169:Number 2(2019)
• Page Start: 409
• Page End: 421
• Publication Date: 2019-02-22
• Subjects: influenza B -- ADE -- antibody-dependent enhancement -- therapeutic antibody -- influenza pneumonia -- DBA/2J mouse model; Toxicology -- Periodicals; Toxicology -- Periodicals; Toxicology; Periodicals; 615.9
• DOI: 10.1093/toxsci/kfz053
• Languages: English
• ISSNs: 1096-6080

Abstract

Abstract: A theoretical safety concern proposed in the influenza literature is that therapeutic antiviral antibodies could have the potential for antibody-dependent enhancement (ADE) of infection and disease. ADE may occur when virus-specific antibodies at subtherapeutic, nonneutralizing concentrations facilitate virus uptake and, in some cases, enhance replication, which can lead to an exacerbation of virus-mediated disease. Alternatively, ADE may occur due to antibody-dependent complement activation exacerbating virus-mediated disease in the absence of increased replication. As a result of this theoretical safety concern, safety assessment of anti-influenza antibodies may include an in vivo evaluation of ADE of infection and/or disease. These studies were conducted to investigate the potential of MHAB5553A, a broadly specific, neutralizing therapeutic anti-influenza B antibody, to elicit ADE of infection and disease in mouse models of influenza B infection. In parallel studies, female DBA/2J mice were infected with either influenza B/Victoria/504/2000 or influenza B/Brisbane/60/2008 representing distinct lineages. Assessment of ADE was based on an integration of results from multiple endpoints, including infectious lung viral titers and genomes, body weight, mortality, lung weight, and histopathology. In these studies, the high dose of 15 mg/kg MHAB5553A resulted in substantial attenuation of influenza pneumonia, with more modest effects at 1.5 mg/kg; whereas MHAB5553A treatment at 0.15 or 0.015 mg/kg was generally comparable to vehicle-treated controls. Our results demonstrate that MHAB5553A across a broad range of doses did not enhance primary influenza B infection or disease in this model, and represent a nonclinical de-risking of the ADE potential with this antibody.